Lupin Ltd shares closed lower on the NSE on August 27 after Citi downgraded the pharmaceutical company to Sell from Buy and cut its target price to ₹2,050 from ₹2,540. The brokerage cited slowing momentum in Lupin’s US base business and uncertainty about replacing revenue from certain high-margin products.
Lupin closed at ₹2,167.20, down ₹17.80, or 0.81%, from ₹2,185 in the previous session. During the day, the stock opened at ₹2,169.60 and touched an intraday low of ₹2,144.70 before recovering part of its decline.
The share-price reaction came as brokerages presented contrasting assessments of Lupin’s US opportunity. While Citi highlighted potential pressure on future US sales and EBITDA margin, Bernstein retained an Outperform rating after a reported favourable court ruling linked to Lupin’s generic ivacaftor programme.
Citi flags a replacement challenge in the US
Citi’s downgrade focuses on the sustainability of Lupin’s US earnings base. The brokerage expects pressure from the erosion of certain established, high-margin products and sees limited visibility on the timing and scale of revenue replacement from the company’s future pipeline.
It identified generic Jynarque and generic Myrbetriq among products where revenue erosion could become significant. Citi said Lupin has opportunities in products including apixaban, Neulasta Onpro, etanercept and Spiriva Respimat, but noted that some of these programmes had not yet been filed.
According to Citi’s estimates, Lupin’s US sales could decline from about $1.3 billion in FY26 to $975 million by FY29. The brokerage also projected EBITDA margin could fall from 30% in the first quarter of FY27 to about 20% by FY29. These are Citi’s estimates, not guidance issued by Lupin.
The concern is not limited to one medicine or one launch. For a generic-drug company with a sizeable US presence, the timing of new launches, the intensity of competition and the ability to defend product economics can all shape revenue and margin trends. Citi’s report has therefore brought Lupin’s pipeline conversion and US portfolio mix into sharper focus.
Lupin’s August 27 price action
The stock’s intraday low showed the immediate impact of the Citi downgrade. However, Lupin recovered from ₹2,144.70 during the session, suggesting that the market was also considering a separate potential catalyst in the company’s US pipeline.
| Lupin share-price data on August 27 | Price |
| Previous close | ₹2,185.00 |
| Opening price | ₹2,169.60 |
| Intraday low | ₹2,144.70 |
| Closing price | ₹2,167.20 |
| Change at close | -0.81% |
Citi’s ₹2,050 target price was below Lupin’s August 27 closing price. Bernstein, meanwhile, retained a ₹2,707 target price and an Outperform rating. The difference between the two targets reflects divergent assumptions around the company’s US portfolio, launch pipeline and potential revenue trajectory.
Brokerage targets are based on analysts’ assumptions and can change with product launches, regulatory developments, litigation outcomes and financial performance. They are not assurances of a stock’s future price.
Also Read: Nestle Wants a Say as India's Food Warning Label Rules Near D-Day
Bernstein sees value in ivacaftor ruling
Bernstein’s positive assessment followed a reported August 24 ruling by the US District Court for the District of Delaware in the Kalydeco, or ivacaftor, patent matter. Bernstein said the ruling removed a key litigation hurdle for Lupin’s first-to-file generic ivacaftor programme.
The court development is older than Citi’s August 27 downgrade and should be treated as context rather than the day’s main news trigger. The fresh development for the stock was Citi’s rating action and target-price revision.
Bernstein estimated that the generic ivacaftor opportunity could generate annual sales of $20 million to $30 million for Lupin. Although this could be a useful pipeline catalyst, the estimate is smaller than the scale of the US sales decline envisaged by Citi through FY29.
The court order was not independently reviewed for this report. Accordingly, the implications for Lupin’s generic ivacaftor programme should be attributed to Bernstein’s analysis rather than presented as confirmation of launch timing or a final commercial outcome.
The next US-business signals to watch
Lupin’s future updates on the US market will remain important after the Citi downgrade. Management commentary on existing-product performance, progress in the pipeline and the timing of new launches could help clarify whether the company can offset anticipated erosion in mature products.
Regulatory approvals, patent litigation, settlements and the competitive intensity of generic markets can also affect the value of individual opportunities. Those developments will determine whether Lupin’s US business can sustain growth and margins at levels different from the path projected by Citi.
For now, the August 27 session has highlighted the two forces shaping Lupin’s investment narrative: a brokerage warning about replacement risk in its US portfolio, and a patent-related development that Bernstein believes could support a future generic launch.
